Predicted HIV-1 coreceptor usage among Kenya patients shows a high tendency for subtype d to be cxcr4 tropic

AIDS Research and Therapy

Volumn 9, Issue , 2012, Pages

  Wambui, Veronica ^a   Kiptoo, Michael ^b   Kinyua, Joyceline ^b   Odera, Irene ^b   Muge, Edward ^a   Muiruri, Peter ^c   Lihana, Raphael ^b   Kinyanjui, Peter ^a   Songok, Elijah M ^a,b  

^a UNIVERSITY OF NAIROBI   (Kenya)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c KENYATTA NATIONAL HOSPITAL   (Kenya)

Author keywords

Co receptor usage; HIV 1; Sub type D

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; DNA; DNA FRAGMENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DNA EXTRACTION; DNA SEQUENCE; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYLOGENY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TROPISM;

EID: 84864239690     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-9-22     Document Type: Article

References (31)

1. Weiss RA. How does HIV cause AIDS?. Science 2003, 260(5112):1273-1279.
2. Nelson Michael L. Host genetic influences on HIV-1 pathogenesis. Curr Opin Immunol 1999, 11:466-474.
3. National AIDS and STI Control Programme Kenya AIDS Indicator Survey 2007 2008, Nairobi, Kenya: Preliminary Report. Ministry of Health, National AIDS and STI Control Programme.
4. Berger E, Murphy P, Farber J. Chemokine receptors as HIV-1 coreceptors. Annu Rev Immunol 1999, 17:657-700.
5. Coakley E, Petropoulos CJ, Whitcomb JM. Assessing chemokine co-receptor usage in HIV. Curr Opin Infect Dis 2005, 18(1):9-15.
6. Berger EA. HIV entry and tropism: the chemokine receptor connection. AIDS 1997, 11:S3-S16.
7. Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol 1997, 9:551-562.
8. Berger EA, Doms RA, Fenyo EM, Korber BTM, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J, Weiss RA. A new classification for HIV-1. Nature 1998, 391:240.
9. Lehmann C, Daumer M, Boussaad I, Sing T, Beerenwinkel N, Lengauer T, Schmeisser N, Wyen C, Fatkenheuer G, Kaiser R. Stable co-receptor usage of HIV in patients with ongoing treatment failure on HAART. J Clin Virol 2006, 37(4):300-304.
10. Philpott S, Weiser B, Anastos K, Kitchen CM, Robinson E, Meyer WA, Sacks HS, Brunner C, Burger H. Preferential suppression of CXCR4-specific strains of HIV by antiviral therapy. J Clin Invest 2001, 107(4):431-438.
11. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 1991, 253:71-74.
12. Whitcomb J, Huang W, Fransen S. Development and characterization of a novel single-cycle recombinant-virus assay to determine HIV-1 coreceptor tropism. Antimicrob Agents Chemother 2007, 51:566-575.
13. Sing T, Low AJ, Beerenwinkel N, Sander O, Cheung PK, Domingues FS, Buch J, Daumer M, Kaiser R, Lengauer T, Harrigan PR. Predicting HIV-coreceptor usage based on genetic and clinical covariates. Antivir Ther 2007, 12:1097-1106.
14. Raymond S, Delobel P, Chaix ML, Cazabat M, Encinas S, Bruel P, Sandres-Saune K, Marchou B, Massip P, Izopet J. Genotypic prediction of HIV-1 subtype D tropism. Retrovirology 2011, 8:56.
15. UNAIDS/WHO Epidemiological Fact Sheets on HIV and AIDS-Kenya 2008, http://www.who.int/hiv/pub/epidemiology/pubfacts/en/., UNAIDS/WHO.
16. Ministry Of Health Guidelines for Antiretroviral Therapy Drug Therapy in Kenya Nairobi, Kenya: Ministry Of Health, Third, Ministry Of Health.
17. Kaleebu P, Nankya IL, Yirrell LD, Shafer LA, Shafer LA, Kyosiimire-Lugemwa, Lule BD, Morgan D, Beddows S, Weber J, Whitworth JAG. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D results from a rural ugandan cohort. J Acquir Immune Defic Syndr 2007, 45:28-33.
18. Church DJ, Huang W, Mwatha A, Toma J, Stawiski E, Donnell D, Guay AL, Mmiro F, Musoke P, Jackson BJ, Parkin N, Eshleman HS. HIV-1 tropism and survival in vertically infected Ugandan infants. J Infect Dis 2008, 197(10):1382-1388.
19. Lihana RW, Khamadi SA, Lwembe RM, Kinyua JG, Muriuki JK, Lagat NJ, Okoth FA, Makokha PE, Songok EM. HIV-1 subtype and viral tropism determination for evaluating antiretroviral therapy options: an analysis of archived Kenyan blood samples. BMC Infect Dis 2009, 9:215.
20. Lwembe R, Lihana RW, Ochieng' W, Panikulam A, Mongoina CO, Palakudy T, De Koning H, Ishizaki A, Kageyama S, Musoke R, Owens M, Songok EM, Okoth FA, Ichimura A. Changes in the HIV type 1 envelope gene from non-subtype B type-1 infected children in Kenya. AIDS Res Hum Retroviruses 2009, 25(2):141-148.
21. Baeten JM, Chohan B, Lavreys I, Chohan V, McClelland RS, Certain I, Mandaliya K, Jaoko W, Overbaugh J. HIV-1 sub-type D infection is associated with faster disease progression than sub-type A in spite of similar plasma HIV-1 loads. J Infect Dis 2007, 195(8):1177-1180.
22. Sacktor N, Nakasuija N, Slolasky R, Rezapour M, Robertson K, Musisi S, Katabira E, Ronald A, Clifford D, Laeyendecker O, Quinn T. HIV subtype D is associated with dementia compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis 2009, 49:780-786.
23. Hunt PW, Harrigan PR, Huang W, Bates M, Williamson DW, McCune JM, Price RW, Spudich SS, Lampiris R, Hoh T, Leigler JN, Deeks SG. Prevalence of CXCR4 tropism among antiretroviral treated HIV-infected patients with detectable viremia. J Infect Dis 2006, 194(7):926-930.
24. Deeks SG, Martin JN, Sinclair E. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J Infect Dis 2004, 189:312-321.
25. Harouse JM, Buckner C, Gettie A. CD8+ T cell-mediated CXC chemokine receptor 4-simian/human immunodeficiency virus suppression in dually infected rhesus macaques. Proc Natl Acad Sci USA 2003, 100:10977-10982.
26. Andersson J, Fehniger TE, Patterson BK. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS 1998, 12:123-129.
27. Giovannetti A, Ensoli F, Mazzetta F. CCR5 and CXCR4 chemokine receptor expression and beta-chemokine production during early T cell repopulation induced by highly active anti-retroviral therapy. Clin Exp Immunol 1999, 118:87-94.
28. Brumme ZL, Goodrich J, Mayer HB. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral- naive individuals. J Infect Dis 2005, 192:466-474.
29. Yuan W, Craig S, Si Z, Farzan M, Sodroski J. CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor. J Virol 2004, 78:5448-5457.
30. Boucher CA, Lange JM, Miedema FF. HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 1992, 6:1259-1264.
31. Low AJ, Dong W, Chan D, Sing T, Ronald S, Jensen M, Pillai S, Good B, Harrigan PR. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS 2007, 21(14):17-24.